Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...

Aclaris Therapeutics ( ($ACRS) ) just unveiled an announcement. On January 6, 2026, Aclaris Therapeutics reported positive interim data from a ...

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

Reviva Pharmaceuticals announced positive results from its Phase 3 RECOVER open-label extension study evaluating brilaroxazine for treating schizophrenia. The study demonstrated robust and sustained ...

Gyre Therapeutics announced positive results from its Phase 3 trial of Hydronidone, a treatment for liver fibrosis in patients with chronic hepatitis B (CHB), showing a significant regression in ...

− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, ...

Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said. FDA has approved blinatumomab, a ...

Detailed price information for Immutep Ltd ADR (IMMP-Q) from The Globe and Mail including charting and trades.

Real-time index price for S&P 500 Financials [Sector] (SRFI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...